Imcyse
Manufacturing · Belgium · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Avenue De L'hôpital Giga B34, Sart Tilma...Phone Number
+32 43251100Website
www.imcyse.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Imcyse
Imcyse is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of severe, chronic autoimmune diseases through its innovative Imotope platform. This technology produces synthetic peptides that utilize the patient's immune system to recalibrate abnormal immune responses. The company's robust pipeline includes clinical and pre-clinical programs targeting conditions such as Type 1 Diabetes, Multiple Sclerosis, and Rheumatoid Arthritis. Imcyse collaborates with academic institutions, industry partners, and investors to advance its development and commercialization efforts.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Imcyse your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Imcyse launches new products
Imcyse, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Imcyse had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Imcyse recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Imcyse
Funding: Get notified immidiatlly once Imcyse has new funding data
Website visits: Recent activity has been detected on your website
Check out if Imcyse is spiking on competitors!
Check if Imcyse has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
Imcyse is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Imcyse is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Imcyse.
Imcyse financials insights
Gather financial insights about Imcyse, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series B
$25.6M
Imcyse Tech Stack
A closer look at the technologies used by Imcyse
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Funding
Funding
Funding
Funding
Imcyse News & Media
Imcyse to Present at Oppenheimer 32nd Annual Healthcare Conference
LIÈGE, Belgium, March 14, 2022 (GLOBE NEWSWIRE) -- Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the treatment of severe autoimmune diseases, announced today that Denis Bedoret, M.D., Ph.D., Chief Executive Officer of Imcyse, will participate in a corporate presentation at the Oppenheimer 32nd Annual Healthcare Conference on Thursday, March 17, 2022 at 1:20pm ET. A live webcast of the corporate presentationImcyse Reports Positive Immune Response from Interim Analysis of Phase 2 IMPACT Type 1 Diabetes Study
Positive interim biomarker data supports specific immune signature induced by IMCY-0098 and effect on potentially pathogenic T cellsImcyse Appoints Gene Mack, MBA as Chief Financial Officer
LIÉGE, Belgium, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the treatment of severe autoimmune diseases, today announced the appointment of Gene Mack, MBA, as Chief Financial Officer.Imcyse Raises Additional EUR 21.3 Million in Series B Financing Round - Pfizer Joins as Newest Shareholder
LIÈGE, Belgium, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the treatment of severe autoimmune diseases, today announced that it has concluded a Series B extension financing round, raising EUR 21.3 million (USD 25.8 million). Participants of the new round included existing investors, Biogenosis, Epimede, LSP, Noshaq, Société Régionale d'Investissement de Wallonie (SRIW),
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Imcyse
Sign Up For FreeTo access detailed company insights
Imcyse is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of severe, chronic autoimmune diseases through its innovative Imotope platform. This technology produces synthetic peptides that utilize the patient's immune system to recalibrate abnormal immune responses. The company's robust pipeline includes clinical an... Read More
